Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma
Pinggui Chen,Yaoxuan Li,Yunyan Dai,Zhiming Wang,Yunpeng Zhou,Yi Wang,Gaopeng Li
DOI: https://doi.org/10.2147/jhc.s450460
2024-03-19
Journal of Hepatocellular Carcinoma
Abstract:Pinggui Chen, 1 Yaoxuan Li, 2 Yunyan Dai, 1 Zhiming Wang, 1 Yunpeng Zhou, 1 Yi Wang, 1 Gaopeng Li 1 1 Department of Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi, People's Republic of China; 2 Department of School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China Correspondence: Gaopeng Li, Email Hepatocellular carcinoma (HCC) is the sixth most common cancer globally and the primary cause of death in cancer cases, with significant public health concern worldwide. Despite the overall decline in the incidence and mortality rates of HCC in recent years in recent years, the emergence of metabolic liver disease-related HCC is causing heightened concern, especially in countries like the United States, the United Kingdom, and P.R. China. The escalation of metabolic liver disease-related HCC is attributed to a combination of factors, including genetic predisposition, lifestyle choices, and changes in the living environment. However, the pathogenesis of metabolic liver disease-associated HCC remains imperfect. In this review, we encapsulate the latest advances and essential aspects of the pathogenesis of metabolic liver disease-associated HCC, including alcoholic liver disease (ALD), metabolic dysfunction–associated steatotic liver disease (MASLD), and inherited metabolic liver diseases. Keywords: hepatocellular carcinoma, metabolic liver disease, pathogenesis, alcoholic liver disease, metabolic dysfunction–associated steatotic liver disease Hepatocellular carcinoma (HCC) stands out as the most prevalent and severe form of primary liver cancer globally. It ranks sixth in new cancer cases and third in cancer-related deaths among humans, solidifying its status as one of the deadliest cancers. 1 At present, the predominant etiological factors in clinical HCC cases encompass hepatitis B virus (HBV), hepatitis C virus (HCV), and metabolic diseases. 2 The historical dominance of HBV and HCV as the main causes of HCC is diminishing due to the widespread use of antiviral drugs, resulting in a declining trend in their associated HCC incidence. 3 However, the incidence of metabolic liver disease-associated HCC has shown an upward trend and is gradually supplanting HBV and HCV as the leading cause of HCC. Metabolic liver disease encompasses a group of diseases causing liver damage due to abnormal metabolism in the body. The liver, being the body's largest detoxification organ, converts toxic exogenous substances and endogenous metabolites into non-toxic or highly soluble substances, facilitating their excretion through bile or urine. Abnormal metabolism, induced by factors such as prolonged heavy drinking, high-fat diets, medications, and deficiencies or abnormalities in specific enzymes in the body, leads to a substantial accumulation of toxic substances in the liver, causing severe damage. 4 Recent years have witnessed a rapid increase in the incidence of metabolic liver disease, driven by changes in lifestyles, environments, and hereditary factors, particularly in countries like the United States, China, and Italy. This heightened incidence elevates the risk of HCC. 5 Clinical observations indicate that metabolic liver disease-related HCC has a relatively poorer prognosis and is more aggressive compared to virus-related HCC. 6 Therefore, there is an urgent need to deepen our understanding of the pathogenesis of metabolic liver disease-related HCC, to discover new strategies for its treatment. Alcoholic liver disease is a widespread chronic liver disease, defined as liver damage caused by prolonged excessive alcohol consumption, typically developing after five consecutive years of average daily alcohol intake of >40 g for men and >20 g for women. 7,8 Alcoholic liver disease (ALD) disease progression is progressive. It initially presents as simple hepatic steatosis, known as alcoholic fatty liver (AFL). About 10–35% of AFL cases progress to alcoholic steatohepatitis (ASH), marked by hepatic inflammation, hepatocellular injury, and ballooning. While ASH progresses gradually, sustained heavy alcohol consumption accelerates its advancement, leading to irreversible fibrosis and cirrhosis. Ultimately, this progression may result in HCC. 9 Reports indicate that more than 90% of individuals with prolonged high alcohol consumption (>40 g per day) will develop AFL, establishing the groundwork for the high prevalence of AFL-HCC. 10 The pathogenesis of metabolic liver disease-related HCC is complex, primarily encompassing metabolism, inflammation, DNA mutation, immunosuppression, and other mechanisms. -Abstract Truncated-
oncology